vs

Side-by-side financial comparison of APPLIED OPTOELECTRONICS, INC. (AAOI) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Ultragenyx Pharmaceutical Inc. is the larger business by last-quarter revenue ($207.3M vs $134.3M, roughly 1.5× APPLIED OPTOELECTRONICS, INC.). On growth, APPLIED OPTOELECTRONICS, INC. posted the faster year-over-year revenue change (33.9% vs 25.9%). Ultragenyx Pharmaceutical Inc. produced more free cash flow last quarter ($-100.8M vs $-104.6M). Over the past eight quarters, APPLIED OPTOELECTRONICS, INC.'s revenue compounded faster (81.7% CAGR vs 38.0%).

Applied Optoelectronics Inc. is an American semiconductor company that focuses on optical devices. It was founded in 1997 at the University of Houston and is headquartered in Sugar Land, Texas.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

AAOI vs RARE — Head-to-Head

Bigger by revenue
RARE
RARE
1.5× larger
RARE
$207.3M
$134.3M
AAOI
Growing faster (revenue YoY)
AAOI
AAOI
+8.0% gap
AAOI
33.9%
25.9%
RARE
More free cash flow
RARE
RARE
$3.8M more FCF
RARE
$-100.8M
$-104.6M
AAOI
Faster 2-yr revenue CAGR
AAOI
AAOI
Annualised
AAOI
81.7%
38.0%
RARE

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AAOI
AAOI
RARE
RARE
Revenue
$134.3M
$207.3M
Net Profit
$-128.6M
Gross Margin
31.2%
Operating Margin
-8.6%
-54.7%
Net Margin
-62.0%
Revenue YoY
33.9%
25.9%
Net Profit YoY
3.5%
EPS (diluted)
$-0.02
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AAOI
AAOI
RARE
RARE
Q4 25
$134.3M
$207.3M
Q3 25
$118.6M
$159.9M
Q2 25
$103.0M
$166.5M
Q1 25
$99.9M
$139.3M
Q4 24
$100.3M
$164.6M
Q3 24
$65.2M
$139.5M
Q2 24
$43.3M
$147.0M
Q1 24
$40.7M
$108.8M
Net Profit
AAOI
AAOI
RARE
RARE
Q4 25
$-128.6M
Q3 25
$-17.9M
$-180.4M
Q2 25
$-9.1M
$-115.0M
Q1 25
$-9.2M
$-151.1M
Q4 24
$-133.2M
Q3 24
$-17.8M
$-133.5M
Q2 24
$-26.1M
$-131.6M
Q1 24
$-23.2M
$-170.7M
Gross Margin
AAOI
AAOI
RARE
RARE
Q4 25
31.2%
Q3 25
28.0%
Q2 25
30.3%
Q1 25
30.6%
Q4 24
28.7%
Q3 24
24.4%
Q2 24
22.1%
Q1 24
18.7%
Operating Margin
AAOI
AAOI
RARE
RARE
Q4 25
-8.6%
-54.7%
Q3 25
-15.3%
-106.9%
Q2 25
-15.5%
-64.8%
Q1 25
-8.9%
-102.6%
Q4 24
-6.5%
-74.3%
Q3 24
-25.4%
-94.6%
Q2 24
-60.7%
-79.1%
Q1 24
-53.2%
-151.9%
Net Margin
AAOI
AAOI
RARE
RARE
Q4 25
-62.0%
Q3 25
-15.1%
-112.8%
Q2 25
-8.8%
-69.0%
Q1 25
-9.2%
-108.5%
Q4 24
-80.9%
Q3 24
-27.3%
-95.7%
Q2 24
-60.4%
-89.5%
Q1 24
-57.0%
-156.8%
EPS (diluted)
AAOI
AAOI
RARE
RARE
Q4 25
$-0.02
$-1.28
Q3 25
$-0.28
$-1.81
Q2 25
$-0.16
$-1.17
Q1 25
$-0.18
$-1.57
Q4 24
$-2.82
$-1.34
Q3 24
$-0.42
$-1.40
Q2 24
$-0.66
$-1.52
Q1 24
$-0.60
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AAOI
AAOI
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$206.1M
$421.0M
Total DebtLower is stronger
$34.0M
Stockholders' EquityBook value
$733.9M
$-80.0M
Total Assets
$1.2B
$1.5B
Debt / EquityLower = less leverage
0.05×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AAOI
AAOI
RARE
RARE
Q4 25
$206.1M
$421.0M
Q3 25
$137.0M
$202.5M
Q2 25
$64.7M
$176.3M
Q1 25
$51.1M
$127.1M
Q4 24
$67.4M
$174.0M
Q3 24
$34.1M
$150.6M
Q2 24
$10.7M
$480.7M
Q1 24
$8.4M
$112.3M
Total Debt
AAOI
AAOI
RARE
RARE
Q4 25
$34.0M
Q3 25
Q2 25
Q1 25
$22.1M
Q4 24
$26.7M
Q3 24
$29.5M
Q2 24
$22.5M
Q1 24
$24.1M
Stockholders' Equity
AAOI
AAOI
RARE
RARE
Q4 25
$733.9M
$-80.0M
Q3 25
$559.1M
$9.2M
Q2 25
$425.0M
$151.3M
Q1 25
$309.0M
$144.2M
Q4 24
$229.1M
$255.0M
Q3 24
$212.1M
$346.8M
Q2 24
$186.5M
$432.4M
Q1 24
$195.7M
$140.3M
Total Assets
AAOI
AAOI
RARE
RARE
Q4 25
$1.2B
$1.5B
Q3 25
$978.5M
$1.2B
Q2 25
$796.9M
$1.3B
Q1 25
$644.7M
$1.3B
Q4 24
$547.0M
$1.5B
Q3 24
$410.0M
$1.5B
Q2 24
$348.0M
$1.6B
Q1 24
$350.9M
$1.3B
Debt / Equity
AAOI
AAOI
RARE
RARE
Q4 25
0.05×
Q3 25
Q2 25
Q1 25
0.07×
Q4 24
0.12×
Q3 24
0.14×
Q2 24
0.12×
Q1 24
0.12×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AAOI
AAOI
RARE
RARE
Operating Cash FlowLast quarter
$-29.6M
$-99.8M
Free Cash FlowOCF − Capex
$-104.6M
$-100.8M
FCF MarginFCF / Revenue
-77.9%
-48.6%
Capex IntensityCapex / Revenue
55.9%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-353.6M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AAOI
AAOI
RARE
RARE
Q4 25
$-29.6M
$-99.8M
Q3 25
$-28.5M
$-91.4M
Q2 25
$-65.5M
$-108.3M
Q1 25
$-50.9M
$-166.5M
Q4 24
$-24.6M
$-79.3M
Q3 24
$-14.4M
$-67.0M
Q2 24
$-2.0M
$-77.0M
Q1 24
$-28.5M
$-190.7M
Free Cash Flow
AAOI
AAOI
RARE
RARE
Q4 25
$-104.6M
$-100.8M
Q3 25
$-78.7M
$-92.7M
Q2 25
$-91.0M
$-110.7M
Q1 25
$-79.3M
$-167.8M
Q4 24
$-53.0M
$-79.5M
Q3 24
$-20.7M
$-68.6M
Q2 24
$-5.0M
$-79.0M
Q1 24
$-34.2M
$-193.9M
FCF Margin
AAOI
AAOI
RARE
RARE
Q4 25
-77.9%
-48.6%
Q3 25
-66.3%
-58.0%
Q2 25
-88.3%
-66.5%
Q1 25
-79.4%
-120.5%
Q4 24
-52.9%
-48.3%
Q3 24
-31.8%
-49.2%
Q2 24
-11.5%
-53.7%
Q1 24
-84.2%
-178.2%
Capex Intensity
AAOI
AAOI
RARE
RARE
Q4 25
55.9%
0.5%
Q3 25
42.4%
0.8%
Q2 25
24.7%
1.5%
Q1 25
28.4%
1.0%
Q4 24
28.3%
0.1%
Q3 24
9.7%
1.2%
Q2 24
6.9%
1.4%
Q1 24
14.2%
3.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AAOI
AAOI

Data Center$74.9M56%
CATV$54.0M40%
Telecom$5.1M4%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons